 The study found that microarray patches, maps, could be a cost-effective way to increase access to hepatitis B vaccines in low and middle income countries, who makes. The study looked at the cost-effectiveness of using maps to expand birth dose coverage outside of health facility settings, as well as the potential for maps to replace some existing coverage from vaccine vials. The study found that maps could be cost-effective if they were priced at slash bin slash SH65 per dose or less. At this price point, maps would be cost-effective in 73 out of 80 Ilmik studied. This article was authored by Christopher P. Seaman, Mercy Vendura, CalRain Friveld, and others.